Victor Moreno Garcia is a distinguished leader in the field of oncology, currently serving as the Director of Clinical Research at START Madrid FJD, an esteemed institution dedicated to the early clinical development of innovative cancer therapies. With a robust educational background that includes a...
Victor Moreno Garcia is a distinguished leader in the field of oncology, currently serving as the Director of Clinical Research at START Madrid FJD, an esteemed institution dedicated to the early clinical development of innovative cancer therapies. With a robust educational background that includes a Medical Degree from the University Complutense of Madrid and specialized training in Medical Oncology at Hospital Universitario La Paz, Victor has cultivated a deep understanding of both the clinical and molecular underpinnings of cancer treatment. His expertise is further enhanced by a Master’s Degree in Molecular Oncology from the Spanish National Cancer Research Centre (CNIO), positioning him at the forefront of translational research.
At START Madrid FJD, Victor plays a pivotal role in spearheading key projects aimed at accelerating the development of novel anticancer drugs. His leadership is instrumental in designing and implementing early-phase clinical trials that not only assess the efficacy and safety of new therapies but also contribute to a deeper understanding of cancer biology. Victor’s commitment to advancing clinical research is evident in his collaborative efforts with pharmaceutical companies and academic institutions, fostering an environment of innovation and scientific inquiry.
In addition to his research endeavors, Victor is passionate about medical education, actively engaging in teaching and mentoring the next generation of oncologists. His multifaceted expertise encompasses clinical research, pharmaceutical industry dynamics, and healthcare delivery, making him a vital asset to the oncology community. Through his work at START, Victor Moreno Garcia continues to make significant strides in improving patient outcomes and shaping the future of cancer treatment.
